License for Protein Production Technology Granted to AgResearch.
Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHAR.AS) announced today a partnership with AgResearch Limited ("AgResearch") on the production of recombinant human lactoferrin ("rhLF"). In addition, Pharming has granted AgResearch a research license to its proprietary protein production technology.

Pharming and AgResearch have partnered on the manufacturing of recombinant human lactoferrin. AgResearch will be responsible for the production of rhLF and will provide access to its purification as well as research capabilities for product development. AgResearch shall bear costs associated with the initial production of rhLF and support the commercialization of rhLF through its extensive network in the South Pacific and Asia.

"The alliance with AgResearch is in line with Pharming's strategy to form partnerships for the manufacturing and commercialization of its products," said Dr. Frank Pieper, CSO of Pharming. "In addition, Pharming is pleased to provide AgResearch a license to its protein production technology and expects further licensing of the technology for various applications."

Pharming has granted AgResearch a research license to its proprietary technology for the production of recombinant proteins. In return, Pharming will have the first right to review new products arising out of AgResearch's protein discovery and R&D projects. The commercial rights of Pharming will cover recombinant bovine and human proteins produced using its proprietary technology.

Pharming is currently preparing a filing on rhLF for Generally Recognized as Safe ("GRAS") registration with the US Food and Drug Administration ("FDA"). Results from toxicology studies demonstrated that rhLF can be consumed orally at high amounts with no adverse effect.